Executive Ownership and Control in Newly Public Firms: The Role of Venture Capitalists

Malcolm  Baker; Paul  Gompers

Abstract

We study the implications of CEO equity ownership for incentives and control in a sample of 1,011 newly public firms. Before an initial public offering, equity investments by venture capitalists reduce CEO ownership by about half, from an average of 35 percent to 19 percent. Venture capitalists narrow this difference by granting options, reducing secondary sales, and lowering the dilution by primary shares, but a gap in post-IPO CEO equity ownership remains. The effect of this lower ownership on incentives depends upon the measure employed - the dollar sensitivity of CEO pay to firm value is lower in venture firms, but the elasticity is about the same. In addition, we present evidence that lower ownership, combined with concentrated outside holdings, leads to a reduction in the agency costs of managerial control. We conclude that the patterns of ownership in part represent a tradeoff by venture capitalists between the benefits of incentives and the agency costs of control.

Language: English

Format: Print

Read Now

More from these Authors

Supplement | HBS Case Collection | April 2018

Celgene

Malcolm Baker and Emily R. McComb

In February 2011, Adam Koppel, a Managing Director at Brookside Capital, the public equity arm of Bain Capital, must decide whether to increase or exit the firm’s position in Celgene Corporation. News has emerged that raises potential safety concerns associated with Celgene’s key drug, Revlimid. In response, Celgene’s share price has traded down 20% in the last two months, and is now almost 10% below the level where Brookside made their initial investment.

Keywords: life sciences; biotechnology; public market investing; Celgene; Revlimid; hedge fund; valuation; growth stocks; Valuation; Investment; Decision Choices and Conditions; Analysis;

Citation:
Baker, Malcolm, and Emily R. McComb. "Celgene." Harvard Business School Spreadsheet Supplement 218-743, April 2018. View Details

Cite View Details Purchase Related
Case | HBS Case Collection | March 2018

Clover Food Lab

Paul Gompers and Silpa Kovvali

Citation:
Gompers, Paul, and Silpa Kovvali. "Clover Food Lab." Harvard Business School Case 818-073, March 2018. View Details

Cite View Details Educators Related
Case | HBS Case Collection | March 2018

Celgene

Malcolm Baker and Emily McComb

In February 2011, Adam Koppel, a Managing Director at Brookside Capital, the public equity arm of Bain Capital, must decide whether to increase or exit the firm’s position in Celgene Corporation. News has emerged that raises potential safety concerns associated with Celgene’s key drug, Revlimid. In response, Celgene’s share price has traded down 20% in the last two months, and is now almost 10% below the level where Brookside made their initial investment.

Keywords: life sciences; biotechnology; public market investing; Celgene; Revlimid; hedge fund; valuation; growth stocks; Valuation; Investment; Decision Choices and Conditions; Analysis; Biotechnology Industry;

Citation:
Baker, Malcolm, and Emily McComb. "Celgene." Harvard Business School Case 218-094, March 2018. View Details

Cite View Details Educators Related

Faculty & Research

Executive Ownership and Control in Newly Public Firms: The Role of Venture Capitalists

Abstract

Citation:

About the Authors

More from these Authors